How to access Dupixent from the UAE — the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

A UAE patient with severe atopic dermatitis, moderate-to-severe asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, or prurigo nodularis may receive a prescription for Dupixent (dupilumab) from their treating dermatologist, pulmonologist, allergist, or gastroenterologist. Dupixent is FDA-approved in the United States and is co-developed by Sanofi and Regeneron. While dupilumab is broadly available through hospital pharmacies in the Emirates, individual cases still arise where a specific indication is not on a hospital formulary, the prescribed dose form is not locally stocked, or an insurer declines reimbursement — in those cases, a named-patient import route remains legitimate.

This guide explains the pathway, what documentation your physician needs, typical costs and timing, and where Reserve Meds fits in.

The clinical situation

Dupixent is a fully human monoclonal antibody that inhibits IL-4 and IL-13 signalling. It is administered as a subcutaneous injection at home on a fortnightly schedule after an initial loading dose. Eligibility depends on indication: documented severity for atopic dermatitis, uncontrolled type-2 inflammation asthma despite standard controller therapy, biopsy-confirmed eosinophilic esophagitis, and so on. Your treating physician confirms eligibility, initial loading regimen, and long-term monitoring plan per FDA labeling.

Is Dupixent legally importable into the UAE?

Yes — through the UAE Ministry of Health and Prevention (MoHAP) named-patient import framework, with parallel authority through the Department of Health Abu Dhabi (DoH) and the Dubai Health Authority (DHA) depending on where your prescribing facility sits. The named-patient mechanism allows a UAE-licensed physician to import a medicine where: (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent locally available option fits the patient, (c) the physician takes clinical responsibility, and (d) chain of custody is documented.

Dupilumab is in fact registered in the UAE for several indications, so most patients access it locally. The named-patient pathway becomes relevant when the specific indication is not on a local formulary, when the specific pre-filled pen or pediatric strength is out of stock, or when the insurance denial makes private import the faster route for the family.

How the pathway works, step by step

1. Consultation with your treating physician. The decision to prescribe Dupixent is clinical, supported by severity documentation and rationale.
2. Confirming the import rationale. Your physician documents why a named-patient import is appropriate (indication, dose form, supply gap, or insurer context).
3. MoHAP named-patient application. Your physician or the hospital pharmacy files the application with clinical rationale, patient reference, product details, and chain-of-custody plan.
4. US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure product from authorised distribution.
5. Cold-chain shipment. Dupixent ships with continuous temperature monitoring at 2–8°C with chain-of-custody documentation end to end.
6. Arrival and first injection. The dispensing location releases product for self-injection at home after training, or administers at the clinic for the first dose.

What documentation your physician needs

Your physician will typically need to provide:

• A clinical rationale letter confirming diagnosis, severity, prior therapies, and Dupixent as the indicated treatment
• Verification of their UAE medical licence
• Identification of the receiving facility for release
• Patient identifier (anonymised reference where possible)
• Planned dosing regimen (loading dose + fortnightly maintenance)

Reserve Meds provides a physician documentation kit that bundles the templates most MoHAP reviewers expect to see for IL-4/IL-13 biologics.

Costs and timing

Dupixent's US cash-pay reference price for two pre-filled pens (one month of maintenance) sits in a broad indicative range of roughly USD 3,500–4,000, with loading doses costing more. Cold-chain logistics, MoHAP documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake. These ranges are indicative, not guaranteed.

Indicative timing — not guaranteed — for first dose after cohort intake opens is approximately 10–21 days from the moment a complete application is submitted to MoHAP. Subsequent maintenance doses ship on a rolling basis against your dosing calendar.

Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.

Reserve Meds's role

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Dupixent specifically, we provide:

• Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
• Documentation. Regulatory package for your physician and for MoHAP review.
• Logistics. Cold-chain, temperature-monitored shipment coordination.
• Concierge case lead. A named point of contact for your family and your physician.

What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating physician. We operate on a waitlist basis during pre-launch.

Frequently asked

Isn't Dupixent already available locally? For many indications, yes — and if locally-stocked product is appropriate for your case, your physician may prescribe it directly. The named-patient pathway is for gap situations: indication not on local formulary, dose form not stocked, or an insurer/supply issue that makes private import the faster route.

Is this legal? Yes, when executed through the MoHAP named-patient framework with appropriate documentation. See our trust and compliance page.

Can I self-inject at home? Yes. Dupixent is designed for patient or caregiver self-injection after clinic training. Your physician and the clinic pharmacist will guide the first dose.

Will insurance cover this? Cash-pay is the default. Some UAE insurers reimburse named-patient imports case by case; we provide documentation for your submission but do not process insurance claims directly.

Next step — join the first-cohort waitlist

Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Dupixent coordination in the UAE.

> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.

Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.